255 related articles for article (PubMed ID: 23196937)
1. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ
AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937
[TBL] [Abstract][Full Text] [Related]
2. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.
Lodi S; Guiguet M; Costagliola D; Fisher M; de Luca A; Porter K;
J Natl Cancer Inst; 2010 Jun; 102(11):784-92. PubMed ID: 20442214
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.
Jaffe HW; De Stavola BL; Carpenter LM; Porter K; Cox DR;
AIDS; 2011 Jul; 25(11):1395-403. PubMed ID: 21572307
[TBL] [Abstract][Full Text] [Related]
5. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
6. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study.
Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945
[TBL] [Abstract][Full Text] [Related]
7. Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015.
Poizot-Martin I; Lions C; Cheret A; Rey D; Duvivier C; Jacomet C; Allavena C; Huleux T; Bani-Sadr F; Obry-Roguet V; Makinson A;
AIDS; 2020 Mar; 34(4):569-577. PubMed ID: 31764070
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
Volkow P; Cesarman-Maus G; Garciadiego-Fossas P; Rojas-Marin E; Cornejo-Juárez P
AIDS Res Ther; 2017 May; 14(1):30. PubMed ID: 28558783
[TBL] [Abstract][Full Text] [Related]
9. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
[TBL] [Abstract][Full Text] [Related]
10. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
[TBL] [Abstract][Full Text] [Related]
11. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
12. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
[TBL] [Abstract][Full Text] [Related]
13. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
14. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ;
Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234
[TBL] [Abstract][Full Text] [Related]
16. Early development of immune reconstitution inflammatory syndrome related to Pneumocystis pneumonia after antiretroviral therapy.
Mok HP; Hart E; Venkatesan P
Int J STD AIDS; 2014 Apr; 25(5):373-7. PubMed ID: 24122663
[TBL] [Abstract][Full Text] [Related]
17. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.
; Rohner E; Schmidlin K; Zwahlen M; Chakraborty R; Clifford G; Obel N; Grabar S; Verbon A; Noguera-Julian A; Collins IJ; Rojo P; Brockmeyer N; Campbell M; Chêne G; Prozesky H; Eley B; Stefan DC; Davidson A; Chimbetete C; Sawry S; Davies MA; Kariminia A; Vibol U; Sohn A; Egger M; Bohlius J
Clin Infect Dis; 2016 Nov; 63(9):1245-1253. PubMed ID: 27578823
[TBL] [Abstract][Full Text] [Related]
18. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991.
Muñoz A; Schrager LK; Bacellar H; Speizer I; Vermund SH; Detels R; Saah AJ; Kingsley LA; Seminara D; Phair JP
Am J Epidemiol; 1993 Feb; 137(4):423-38. PubMed ID: 8096356
[TBL] [Abstract][Full Text] [Related]
19. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution inflammatory syndrome: incidence and implications for mortality.
Novak RM; Richardson JT; Buchacz K; Chmiel JS; Durham MD; Palella FJ; Wendrow A; Wood K; Young B; Brooks JT;
AIDS; 2012 Mar; 26(6):721-30. PubMed ID: 22233655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
